Loading organizations...
Based in Natick, Massachusetts, AvengeBio is a clinical-stage biotechnology company that develops cell-based immunotherapies for the treatment of intractable solid tumors. The organization utilizes its proprietary LOCOcyte platform to engineer allogeneic cells that deliver high concentrations of immune-stimulating molecules directly to the local tumor environment, targeting difficult indications such as ovarian, lung, and breast cancers. Prior to reportedly ceasing operations in early 2024 due to macroeconomic fundraising challenges, the pre-revenue enterprise advanced its lead platinum-resistant ovarian cancer candidate into Phase 1/2 clinical trials. The firm previously secured $45 million in a 2022 Series A financing round backed by venture capital investors including Perceptive Xontogeny Venture Fund, CAM Capital, Rock Springs Capital, and Longitude Capital. Leveraging technology originally developed at Rice University, AvengeBio was founded in 2019 by Michael Heffernan, Omid Veiseh, and Paul Wotton.
AvengeBio has raised $45.0M across 1 funding round.
AvengeBio has raised $45.0M in total across 1 funding round.
AvengeBio has raised $45.0M across 1 funding round. Most recently, it raised $45.0M Series A in January 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 10, 2022 | $45M Series A | BEN Askew, CAM Capital, Perceptive Xontogeny Venture Fund | Josh Richardson, Pappas Capital, Rock Springs Capital | Announced |
AvengeBio has raised $45.0M in total across 1 funding round.
AvengeBio's investors include Ben Askew, CAM Capital, Perceptive Xontogeny Venture Fund, Josh Richardson, Pappas Capital, Rock Springs Capital.
